Shamburg News · 8-K filed Nov 10, 2026, 8:08 AM EST

Corbus Pharmaceuticals Reports Q3 2026 Net Loss of $37.8 Million, Starts TEMPO-1 Trial

CRBP · Corbus Pharmaceuticals Holdings, Inc.

  • Earnings
  • Other event
  • Leadership change
  • Materiality: high

Corbus Pharmaceuticals reported a net loss of approximately $37.8 million, or $1.81 per basic and diluted share, for the quarter ended September 30, 2026, compared with a net loss of approximately $23.3 million, or $1.90 per share, a year earlier. Operating expenses rose to approximately $38.8 million, driven primarily by a $15.0 million development milestone under the CSPC licensing agreement. The company reported $115.3 million in cash, cash equivalents and investments as of September 30, 2026, which it expects to fund operations into 2028, and it disclosed topline CANYON-1 Phase 1b data for CRB-913 and dosing initiation in the TEMPO-1 study.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 9.01, accession 0001193125-26-454476.

Written from the filing by Shamburg Markets. Figures are as reported by the company.